

Tomoko Hayashi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6983996/publications.pdf>

Version: 2024-02-01

70
papers

4,409
citations

159585

30
h-index

106344

65
g-index

71
all docs

71
docs citations

71
times ranked

6101
citing authors

#	ARTICLE	IF	CITATIONS
1	A Triple High Throughput Screening for Extracellular Vesicle Inducing Agents With Immunostimulatory Activity. <i>Frontiers in Pharmacology</i> , 2022, 13, 869649.	3.5	2
2	Generation and Application of a Reporter Cell Line for the Quantitative Screen of Extracellular Vesicle Release. <i>Frontiers in Pharmacology</i> , 2021, 12, 668609.	3.5	32
3	Mitochondria-dependent synthetic small-molecule vaccine adjuvants for influenza virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	6
4	Structure-activity relationship studies in substituted sulfamoyl benzamidothiazoles that prolong NF- κ B activation. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 43, 116242.	3.0	5
5	Synthesis and immunostimulatory activity of sugar-conjugated TLR7 ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126840.	2.2	3
6	A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity. <i>Frontiers in Immunology</i> , 2020, 11, 1207.	4.8	16
7	Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 26637-26647.	8.0	13
8	Structure-Activity Relationship Studies To Identify Affinity Probes in Bis-aryl Sulfonamides That Prolong Immune Stimuli. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9521-9540.	6.4	8
9	Delivery of Immunotherapeutic Nanoparticles to Tumors via Enzyme-Directed Assembly. <i>Advanced Healthcare Materials</i> , 2019, 8, e1901105.	7.6	35
10	Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model. <i>Cancer Immunology Research</i> , 2019, 7, 1714-1726.	3.4	72
11	Gold Nanoparticles Coimmobilized with Small Molecule Toll-Like Receptor 7 Ligand and α -Mannose as Adjuvants. <i>Bioconjugate Chemistry</i> , 2019, 30, 2811-2821.	3.6	18
12	Discovery of a Novel Microtubule Targeting Agent as an Adjuvant for Cancer Immunotherapy. <i>BioMed Research International</i> , 2018, 2018, 1-13.	1.9	10
13	Recent Advances and Perspectives in Small-molecule TLR Ligands and Their Modulators. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 1156-1159.	2.8	14
14	Identification of Compounds That Prolong Type I Interferon Signaling as Potential Vaccine Adjuvants. <i>SLAS Discovery</i> , 2018, 23, 960-973.	2.7	9
15	Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6836-E6844.	7.1	17
16	Cell-penetrating peptide CGKRK mediates efficient and widespread targeting of bladder mucosa following focal injury. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 1925-1932.	3.3	21
17	Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice. <i>Journal of Virology</i> , 2017, 91, .	3.4	32
18	Identification of Biologically Active Pyrimido[5,4- <i>b</i>]indoles That Prolong NF- κ B Activation without Intrinsic Activity. <i>ACS Combinatorial Science</i> , 2017, 19, 533-543.	3.8	19

#	ARTICLE	IF	CITATIONS
19	Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. <i>JCI Insight</i> , 2017, 2, .	5.0	203
20	The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity. <i>Cell</i> , 2016, 167, 1525-1539.e17.	28.9	318
21	Induction of Tolerogenic Dendritic Cells by a PEGylated TLR7 Ligand for Treatment of Type 1 Diabetes. <i>PLoS ONE</i> , 2015, 10, e0129867.	2.5	27
22	Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses. <i>Journal of Virology</i> , 2015, 89, 3221-3235.	3.4	92
23	Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. <i>Bioconjugate Chemistry</i> , 2015, 26, 1713-1723.	3.6	38
24	Innate Immune Protection against Infectious Diseases by Pulmonary Administration of a Phospholipid-Conjugated TLR7 Ligand. <i>Journal of Innate Immunity</i> , 2014, 6, 315-324.	3.8	16
25	TLR4-dependent activation of dendritic cells by an HMGB1-derived peptide adjuvant. <i>Journal of Translational Medicine</i> , 2014, 12, 211.	4.4	75
26	Discovery of substituted 4-aminoquinazolines as selective Toll-like receptor 4 ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4931-4938.	2.2	20
27	Novel Synthetic Toll-Like Receptor 4/MD2 Ligands Attenuate Sterile Inflammation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 330-340.	2.5	15
28	Fluorescent-tilmanocept for tumor margin analysis in the mouse model. <i>Journal of Surgical Research</i> , 2014, 190, 528-534.	1.6	14
29	Identification of Substituted Pyrimido[5,4- <i>b</i>]indoles as Selective Toll-Like Receptor 4 Ligands. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4206-4223.	6.4	76
30	Increased aldehyde dehydrogenase activity in high-risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 400-402.	1.3	4
31	Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue. <i>Journal of Mass Spectrometry</i> , 2013, 48, 768-773.	1.6	22
32	Localized <i>In Vivo</i> Activation of a Photoactivatable Doxorubicin Prodrug in Deep Tumor Tissue. <i>Photochemistry and Photobiology</i> , 2013, 89, 698-708.	2.5	18
33	Inhibition of keratinocyte proliferation by phospholipid-conjugates of a TLR7 ligand in a Myc-induced hyperplastic actinic keratosis model in the absence of systemic side effects. <i>European Journal of Dermatology</i> , 2013, 23, 618-628.	0.6	9
34	Mast Cell-Mediated Inhibition of Abdominal Neutrophil Inflammation by a PEGylated TLR7 Ligand. <i>Mediators of Inflammation</i> , 2012, 2012, 1-10.	3.0	7
35	Cutting Edge: Nitrogen Bisphosphonate-Induced Inflammation Is Dependent upon Mast Cells and IL-1. <i>Journal of Immunology</i> , 2012, 188, 2977-2980.	0.8	24
36	Importance of Toll-Like Receptor 9 in Host Defense against M1T1 Group A <i>Streptococcus</i> Infections. <i>Journal of Innate Immunity</i> , 2012, 4, 213-218.	3.8	32

#	ARTICLE	IF	CITATIONS
37	Analysis of high-throughput screening assays using cluster enrichment. <i>Statistics in Medicine</i> , 2012, 31, 4175-4189.	1.6	17
38	Treatment of Autoimmune Inflammation by a TLR7 Ligand Regulating the Innate Immune System. <i>PLoS ONE</i> , 2012, 7, e45860.	2.5	20
39	Synthesis and Characterization of PEGylated Toll Like Receptor 7 Ligands. <i>Bioconjugate Chemistry</i> , 2011, 22, 445-454.	3.6	30
40	The Role of Plasmacytoid and Myeloid Dendritic Cells in Induction of Asthma in a Mouse Model and the Effect of a TLR9 Agonist on Dendritic Cells. <i>Allergy, Asthma and Immunology Research</i> , 2011, 3, 199.	2.9	9
41	Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2. <i>Melanoma Research</i> , 2011, 21, 66-75.	1.2	22
42	Role of IL-1 receptor-associated kinase-M (IRAK-M) in priming of immune and inflammatory responses by nitrogen bisphosphonates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 11163-11168.	7.1	22
43	Intravesical Toll-like receptor 7 agonist R837: Optimization of its formulation in an orthotopic mouse model of bladder cancer. <i>International Journal of Urology</i> , 2010, 17, 483-490.	1.0	26
44	Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 7479-7484.	7.1	112
45	Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2764-2769.	7.1	100
46	Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates. <i>Bioconjugate Chemistry</i> , 2009, 20, 1194-1200.	3.6	95
47	In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model. <i>Cellular Immunology</i> , 2008, 251, 78-85.	3.0	21
48	Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2008, 295, R123-R132.	1.8	32
49	3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 18619-18624.	7.1	161
50	Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3990-3995.	7.1	98
51	A traditional Japanese medicine mitigates TNBS-induced colitis in rats. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 1183-1189.	1.5	12
52	TLR9-Based Immunotherapy for Allergic Disease. <i>American Journal of Medicine</i> , 2006, 119, 897.e1-897.e6.	1.5	46
53	Vaccination with Irradiated <i>Listeria</i> Induces Protective T Cell Immunity. <i>Immunity</i> , 2006, 25, 143-152.	14.3	86
54	CpG oligonucleotides partially inhibit growth of <i>Mycobacterium tuberculosis</i> , but not <i>Salmonella</i> or <i>Listeria</i> , in human monocyte-derived macrophages. <i>FEMS Immunology and Medical Microbiology</i> , 2005, 45, 303-310.	2.7	12

#	ARTICLE	IF	CITATIONS
55	Induction and Inhibition of the Th2 Phenotype Spread: Implications for Childhood Asthma. <i>Journal of Immunology</i> , 2005, 174, 5864-5873.	0.8	21
56	Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. <i>Gastroenterology</i> , 2004, 126, 520-528.	1.3	817
57	Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 448-454.	2.9	82
58	Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. <i>Journal of Clinical Investigation</i> , 2004, 114, 270-279.	8.2	297
59	IFN- γ Promote Priming of Antigen-Specific CD8+ and CD4+ T Lymphocytes by Immunostimulatory DNA-Based Vaccines. <i>Journal of Immunology</i> , 2002, 168, 4907-4913.	0.8	117
60	Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. <i>Gastroenterology</i> , 2002, 122, 1428-1441.	1.3	333
61	Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. <i>Vaccine</i> , 2002, 20, 3342-3354.	3.8	75
62	Identification of a chemotactic, MCP-1-like protein from <i>Mycobacterium avium</i> . <i>FEMS Immunology and Medical Microbiology</i> , 2002, 33, 115-124.	2.7	8
63	Immunostimulatory DNA-Based Vaccines Elicit Multifaceted Immune Responses Against HIV at Systemic and Mucosal Sites. <i>Journal of Immunology</i> , 2001, 167, 1584-1591.	0.8	100
64	Enhancement of Innate Immunity against <i>Mycobacterium avium</i> Infection by Immunostimulatory DNA Is Mediated by Indoleamine 2,3-Dioxygenase. <i>Infection and Immunity</i> , 2001, 69, 6156-6164.	2.2	71
65	Release of monocyte chemoattractant protein (MCP)-1 by a human alveolar epithelial cell line in response to <i>Mycobacterium avium</i> . <i>FEMS Immunology and Medical Microbiology</i> , 2000, 29, 1-7.	2.7	11
66	Role of CD40 Ligand in <i>Mycobacterium avium</i> Infection. <i>Infection and Immunity</i> , 1999, 67, 3558-3565.	2.2	38
67	Detection of mitochondrial DNA nucleotide 11778 point mutation of Leber hereditary optic neuropathy from archival stained histopathological preparations. <i>Acta Ophthalmologica</i> , 1998, 76, 14-19.	0.3	6
68	Immunobiological activities of chemically defined lipid A from <i>Helicobacter pylori</i> LPS in comparison with <i>Porphyromonas gingivalis</i> lipid A and <i>Escherichia coli</i> -type synthetic lipid A (compound 506). <i>Vaccine</i> , 1997, 15, 1598-1605.	3.8	61
69	A clinico-epidemiological analysis of <i>Helicobacter pylori</i> (<i>H. pylori</i>) by Southern blotting with A urease gene probe. <i>Journal of Gastroenterology</i> , 1994, 29, 120-124.	5.1	13
70	Chromosomal heterogeneity of <i>Helicobacter pylori</i> isolates by pulsed-field gel electrophoresis. <i>Zentralblatt Fur Bakteriologie: International Journal of Medical Microbiology</i> , 1993, 280, 120-127.	0.5	10